Ascendis Pharma Files 6-K for December 2024
Ticker: ASND · Form: 6-K · Filed: Dec 30, 2024 · CIK: 1612042
Sentiment: neutral
Topics: reporting, foreign-private-issuer, registration-statement
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K for Dec 2024, likely related to stock plans.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on December 30, 2024, to report information as a foreign private issuer. The filing is for the month of December 2024 and is incorporated by reference into several of their S-8 registration statements, which are typically used for employee stock plans.
Why It Matters
This filing indicates ongoing reporting requirements for Ascendis Pharma A/S as a foreign private issuer, potentially related to employee stock plans and other corporate actions.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain significant new financial or operational information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Filer of the Form 6-K
- 001-36815 (company) — SEC File Number for Ascendis Pharma A/S
- 333-203040 (company) — Registration statement number incorporated by reference
- 333-210810 (company) — Registration statement number incorporated by reference
- 333-211512 (company) — Registration statement number incorporated by reference
- 333-213412 (company) — Registration statement number incorporated by reference
- 333-214843 (company) — Registration statement number incorporated by reference
- 333-216883 (company) — Registration statement number incorporated by reference
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information that the issuer would be required to make public in its home country or that it has made or will make public elsewhere.
What does the incorporation by reference into Form S-8 registration statements signify?
Incorporation by reference into Form S-8 registration statements typically means that the information in the 6-K filing is relevant to the company's employee stock plans or other equity-based compensation arrangements.
What period does this specific Form 6-K cover?
This Form 6-K report is for the month of December 2024.
What is Ascendis Pharma A/S's principal executive office address?
Ascendis Pharma A/S's principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Is Ascendis Pharma A/S required to file annual reports on Form 20-F?
Yes, the filing indicates that Ascendis Pharma A/S files annual reports under cover of Form 20-F.
Filing Stats: 395 words · 2 min read · ~1 pages · Grade level 15.8 · Accepted 2024-12-30 16:04:27
Key Financial Figures
- $66.86 — cash consideration of approximately USD $66.86 per share, based on the DKK-USD exchang
Filing Documents
- d905429d6k.htm (6-K) — 12KB
- d905429dex11.htm (EX-1.1) — 1202KB
- g905429dsp174.jpg (GRAPHIC) — 3KB
- g905429dsp175.jpg (GRAPHIC) — 3KB
- g905429dsp177.jpg (GRAPHIC) — 3KB
- g905429dsp178.jpg (GRAPHIC) — 3KB
- g905429dsp179.jpg (GRAPHIC) — 3KB
- g905429dsp180.jpg (GRAPHIC) — 5KB
- g905429dsp_24a.jpg (GRAPHIC) — 4KB
- g905429dsp_25a.jpg (GRAPHIC) — 8KB
- g905429dsp_25b.jpg (GRAPHIC) — 3KB
- g905429dsp_26a.jpg (GRAPHIC) — 6KB
- g905429dsp_33a.jpg (GRAPHIC) — 4KB
- g905429dsp_33b.jpg (GRAPHIC) — 8KB
- g905429dsp_34a.jpg (GRAPHIC) — 3KB
- g905429dsp_34b.jpg (GRAPHIC) — 6KB
- g905429page43.jpg (GRAPHIC) — 4KB
- g905429page44a.jpg (GRAPHIC) — 8KB
- g905429page44b.jpg (GRAPHIC) — 3KB
- g905429page45.jpg (GRAPHIC) — 6KB
- 0001193125-24-286856.txt ( ) — 1335KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: December 30, 2024 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer